These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33628621)

  • 61. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
    van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
    Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
    Alouani E; Laparra A; Perret A; Sakkal M; Messayke S; Danlos FX; Ouali K; Hollebecque A; Even C; Ammari S; Baldini C; Champiat S; Besse B; Robert C; Guettier C; Samuel D; Lambotte O; De Martin E; Michot JM
    Eur J Cancer; 2023 Nov; 193():113313. PubMed ID: 37748398
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis.
    Xu S; Shukuya T; Tamura J; Shimamura S; Kurokawa K; Miura K; Miyawaki T; Hayakawa D; Asao T; Yamamoto K; Takahashi K
    JTO Clin Res Rep; 2022 Apr; 3(4):100309. PubMed ID: 35434666
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and discontinuation rate of immune checkpoint inhibitors used in patients with solid and hematological malignancies. A population based retrospective analysis.
    Shahbar A; Alshamrani M; Aseeri M; Alfayea T; Alnatsheh A
    J Oncol Pharm Pract; 2022 Jun; 28(4):771-776. PubMed ID: 34034557
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
    Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
    Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
    Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
    JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
    Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.
    Zaremba A; Kramer R; De Temple V; Bertram S; Salzmann M; Gesierich A; Reinhardt L; Baroudjian B; Sachse MM; Mechtersheimer G; Johnson DB; Weppler AM; Spain L; Loquai C; Dudda M; Pföhler C; Hepner A; Long GV; Menzies AM; Carlino MS; Lebbé C; Enokida T; Tahara M; Bröckelmann PJ; Eigentler T; Kähler KC; Gutzmer R; Berking C; Ugurel S; Stadtler N; Sucker A; Becker JC; Livingstone E; Meier F; Hassel JC; Schadendorf D; Hanoun M; Heinzerling L; Zimmer L
    Front Oncol; 2021; 11():765608. PubMed ID: 34746007
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
    da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
    Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
    Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.
    Smith MK; Chan Y; Suo AE; Shaheen AA; Congly SE; Tandon P; Bhanji RA; Wells MM; Cheng T; Ma C
    J Can Assoc Gastroenterol; 2022 Feb; 5(1):39-47. PubMed ID: 35118226
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
    Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
    Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.